Author

David S. Hong

The University of Texas MD Anderson Cancer CenterORCID 0000-0001-8721-1609Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Assay:DNA methylation· 1 Assay:proteomics· 1

Frequent Co-Authors

Aaliyah Washington· 1 shared Aaron A. Bickert· 1 shared Abdelrahman M.G. YousefiD· 1 shared Adrian PerdyaniD· 1 shared Alberto VidesiD· 1 shared Alexander I. SpiraiD· 1 shared Amari M. SockwelliD· 1 shared Ana S. Maldonado· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaliyah Washington

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyJournal of Hematology & OncologyPeer-reviewedJul 2, 2026

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma

Saikat Chowdhury, Ichiaki Ito, Vinay K. Pattalachinti…·John Paul Shen

This study evaluates KRAS inhibitors in appendiceal adenocarcinoma models and patients, showing efficacy in reducing tumor growth and suggesting potential resistance mechanisms.

2 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 24, 2025

Mechanisms of resistance to active state selective tri-complex RAS inhibitors

Ben Sang, Ling Feng Ye, Feng Hu…·Piro Lito

This study identifies mechanisms of resistance to tri-complex RAS inhibitors in patients with RAS-driven cancers, showing that resistance alterations disrupt the RAS:drug:CYPA tri-complex formation.

12 citations

humanDNA methylation

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 28, 2025

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer

Krishnan K. Mahadevan, Ana S. Maldonado, Bingrui Li…·Raghu Kalluri

This study identifies small molecule Kras inhibitors that synergize with anti-CTLA4 therapy to reprogram Tregs and enhance immunotherapy efficacy in PDAC.

7 citations

humanATAC-seq

𝕏 PostBluesky